Interstitial lung disease & IPF
5 trials- 2019INBUILDProgressive fibrosing ILDIn 663 patients with non-IPF progressive fibrosing ILD, nintedanib slowed annual FVC decline compared with placebo.
- 2019SENSCISSSc-ILDIn 576 patients with SSc-associated ILD, nintedanib slowed annual FVC decline compared with placebo.
- 2014INPULSISAntifibrotic — IPFIn 1,066 patients with idiopathic pulmonary fibrosis, nintedanib 150 mg twice daily slowed annual FVC decline compared with placebo.
- 2014ASCENDAntifibrotic — IPFIn 555 patients with IPF (FVC 50–90% predicted), pirfenidone 2,403 mg/day reduced ≥10% FVC decline or death at 52 weeks compared with placebo.
- 2012PANTHER-IPFImmunosuppression — IPFIn patients with idiopathic pulmonary fibrosis, prednisone + azathioprine + NAC increased mortality and hospitalisation compared with placebo.